Health outcomes in adults with childhood growth hormone deficiency
Part of Bones, joints & muscles, Brain & nervous system, Hormones & metabolism clinical trials.
This study follows adults who had growth hormone deficiency as children and are now part of a research registry. It aims to understand their health outcomes as they transition into adulthood.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You were diagnosed with growth hormone deficiency that started in childhood.
- You are already enrolled in the BELGROW registry (a research database).
- You stopped taking growth hormone for growth after 2011.
- A doctor confirmed that your growth hormone deficiency is still present after stopping treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how different types of growth hormone treatment affect your body’s metabolism and growth. It will compare standard daily growth hormone with a longer-acting version, and track your health over time to see which works better.
This trial tests a new growth hormone treatment called GenSci134 in healthy adults and adults with growth hormone deficiency (AGHD). The goal is to see if it is safe and effective for people who need growth hormone replacement.
This study looks at how growth hormone and related chemicals (like IGF-1) affect growth in children. It includes healthy kids and those with growth problems to better understand normal and delayed growth.
This Phase 2 study tests whether replacing growth hormone can improve symptoms in veterans with Gulf War Illness and adult growth hormone deficiency. It also checks that the treatment is safe for people with stable medications and hormone regimens.
This study follows children who are short for their age and checks how safe and effective growth hormone is over the long term. It may help families understand expected benefits and side effects for their specific growth-related condition.
This study tracks the safety of lonapegsomatropin in children being treated for growth hormone deficiency (GHD). It’s meant to check for side effects and make sure the medicine continues to be safe in real-world use.
Hear when a new Growth Hormone Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.